Jim Simons
MAZE

Jim Simons’s Maze Therapeutics MAZE Stock Holding History

Jim Simons’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,800
Closed -$472K – 3727
2026
Q1 		$472K Sell
15,800
-11,300
-42% -$499K ﹤0.01% 2627
2025
Q4 		$1.12M Sell
27,100
-59,000
-69% -$2.03M ﹤0.01% 2212
2025
Q3 		$2.23M Buy
+86,100
New +$1.45M ﹤0.01% 1995

Other funds holding MAZE

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Jim Simons's MAZE Position: Q2 2026 in Review

Jim Simons sold out of Maze Therapeutics (MAZE) in Q2 2026, closing a stake of 15,800 shares — an estimated $472K sold.

Jim Simons first reported a position in MAZE in Q3 2025 and held it in 3 quarters. The position peaked at $2.23M in Q3 2025. 92 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Jim Simons reported no remaining Maze Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jim Simons sold 15,800 Maze Therapeutics shares in Q2 2026, an estimated $472K.
  • Jim Simons first reported a position in Maze Therapeutics in Q3 2025 and held it in 3 quarters.
  • Jim Simons's Maze Therapeutics position peaked at $2.23M in Q3 2025.
  • 92 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.